Analog Engine REGN · Last run: 4d ago (stale)
BULLISH·Trend (~3 months) · 56% win rate
Base +2.9% → $785.01 · Bull +17.2% → $894.00 · Bear -8.5% → $697.64
Entry: $762.81 · Stop: $697.64 · R/R: 0.3:1
RiskWhale Composite Signal
Scenarios
56% win · base +2.9% · trend
OVERSOLD
-6.9% to base target
BULL REGIME · Health Care sector
Trade setup
SKIP
Analog direction is constructive but entry math does not pay at current levels — wait for better R/R or use a longer timeframe.
$762.81
$697.64
$785.01
0.3:1
REGN Forensic analysis
Detailed research
PART 1: TRADING EXECUTION
Trading Setup & Entry Strategy
REGN is currently in a capitulation phase, evidenced by a sharp 12.87% drop over 5 days and a significantly oversold RSI of 26.20. While the fundamentals are robust, the technical breakdown is severe.
- >Entry Zones: Accumulate 30% at current levels ($630.30). Add 40% only on a re-test of the $610-615 support zone. Keep 30% in reserve for a confirmed reversal (higher high on intraday).
- >Stop Loss: Hard stop at $595.00. A breach of this level invalidates the bullish thesis and suggests a structural shift lower.
- >Take Profit: Target 1: $685 (Gap fill/10-day SMA). Target 2: $730 (Near 50-day SMA).
- >Position Sizing: 3-4% of total portfolio. This is a mean-reversion trade in a bearish-trending tape.
- >Risk/Reward: ~1:2.5.
Executive Summary
Regeneron (REGN) is trading at $630.30, down from recent highs due to a combination of market-wide volatility and a specific melanoma combo trial miss. Despite the negative headlines, the company remains a fundamental powerhouse with $18.21B in current assets and a strong cash-flow generation capability of $1.08B in operating cash flow for Q1 2026. Analysis Date: 2026-05-20.
PART 2: DETAILED RESEARCH
Recent Material Events (8-K Analysis)
- >April 2026: Board authorized an additional $3.0B share repurchase program, signaling confidence in intrinsic value despite the stock's volatility.
- >Regulatory: Ongoing legal battles regarding EYLEA biosimilars (Amgen/Sandoz) and the $2.32B partnership with Parabilis underscore the company's aggressive R&D strategy.
Financial Health
- >Revenue Quality: Strong. High reliance on Dupixent/EYLEA, but growth remains solid. Collaboration revenue of $1.90B shows effective monetization of the Sanofi/Bayer partnerships.
- >Balance Sheet: Excellent liquidity with $8.75B in cash/short-term marketable securities. Net debt is low relative to annual earnings capacity.
Technical Analysis & Trade Timing
- >Trend: The stock is currently in a BEARISH_DOWNTREND with a BEARISH_CROSSING. Price is significantly below the 50-day ($736.73) and 200-day ($692.18) SMAs.
- >Oversold Logic: RSI at 26.20 suggests a tradable bounce is imminent, but avoid 'catching' until we see a bullish intraday reversal candle.
- >Reconciliation: While the fundamental growth story is intact, the technicals demand caution. The "Death Cross" logic applies; we treat this as a high-reward, high-risk mean reversion trade rather than a core long-term buy.
Short-Term Trading Strategy (2-5 Days)
- >Timeframe: Swing Trade (2–5 Days)
- >Max Hold: 7 days.
- >Strategy: Target the gap-fill to the $680-$690 range. If the stock fails to hold $625 over the next 48 hours, exit immediately.
Investment Recommendation
HOLD/BUY-ON-BOUNCE. The stock is currently oversold and decoupled from fair value due to technical liquidations. We advise a disciplined, phased entry.
"The market is overreacting to the melanoma trial data; in a high-cash-flow biotech, this represents an asymmetric entry point for the disciplined trader."